Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Follow-Up Questions
Who is the CEO of Cue Biopharma Inc?
Dr. Usman Azam is the President of Cue Biopharma Inc, joining the firm since 2025.
What is the price performance of CUE stock?
The current price of CUE is $0.82, it has increased 2.98% in the last trading day.
What are the primary business themes or industries for Cue Biopharma Inc?
Cue Biopharma Inc belongs to Biotechnology industry and the sector is Health Care
What is Cue Biopharma Inc market cap?
Cue Biopharma Inc's current market cap is $63.0M
Is Cue Biopharma Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Cue Biopharma Inc, including 2 strong buy, 3 buy, 1 hold, 0 sell, and 2 strong sell
